Literature DB >> 18541264

The use of saline-linked radiofrequency dissecting sealer for liver transection in patients with cirrhosis.

Feng Xia1, Shuguang Wang, Kuansheng Ma, Xiaobing Feng, Yongjie Su, Jiahong Dong.   

Abstract

BACKGROUND: In patients with cirrhosis excessive hemorrhage and the need for blood transfusion are associated with increased postoperative morbidity and mortality as well as a poor long-term outcome. Saline-linked radiofrequency dissecting sealer (TissueLink) is a recent advance in technology that improves hemostasis during difficult liver resections. Preliminary studies have shown that this technique reduces blood loss without inflow occlusion. PATIENTS AND METHODS: A controlled study was performed on 122 consecutive patients with cirrhosis who underwent liver resection for hepatocytotic carcinoma. The outcomes of liver transection with clamp crushing and TissueLink were compared to evaluate which strategy is most beneficial to the patients.
RESULTS: Both intraoperative blood loss and blood transfusion requirements were significantly higher in the crushing clamp group than in the TissueLink group (P = 0.047 and P = 0.031, respectively). In addition, a significantly higher number of patients required a blood transfusion in the crushing clamp group (P < 0.001). However, the transection time was significantly faster in the crushing clamp group than in the TissueLink group (P < 0.001). The number of patients that required Pringle's maneuver was markedly higher in the crushing clamp group (P < 0.001). In addition, the hemostasis time was significantly longer in the crushing clamp group (P < 0.001). The serum aspartate aminotransferase levels 3 and 7 days after surgery were significantly higher in the crushing clamp group than in the TissueLink group (P = 0.035 and P = 0.003, respectively). Serum total bilirubin levels were markedly increased 3 days after surgery in the crushing clamp group than in the TissueLink group (P = 0.011). Biliary leakage occurred in a higher number of crushing clamp patients (six) than TissueLink patients (three), although this difference was not significant. The operative morbidity not including biliary leakage was higher in the crushing clamp group than the TissueLink group (nine patients versus five patients, respectively).
CONCLUSION: This study reveals that the TissueLink procedure has beneficial effects during liver transection under cirrhotic conditions in terms of blood loss and reperfusion-related liver injury. However, this procedure requires a significantly longer transection time of the parenchyma.

Entities:  

Mesh:

Year:  2008        PMID: 18541264     DOI: 10.1016/j.jss.2008.01.002

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  4 in total

1.  Modification of right hepatectomy results in improvement outcome: a retrospective comparative study.

Authors:  Jeff Siu-Wang Wong; Kit-Fai Lee; Yue-Sun Cheung; Ching-Ning Chong; John Wong; Paul Bo-San Lai
Journal:  HPB (Oxford)       Date:  2011-05-05       Impact factor: 3.647

2.  Comparison of liver parenchymal ablation and tissue necrosis in a cadaveric bovine model using the Harmonic Scalpel, the LigaSure, the Cavitron Ultrasonic Surgical Aspirator and the Aquamantys devices.

Authors:  John S Hammond; William Muirhead; Abed M Zaitoun; Iain C Cameron; Dileep N Lobo
Journal:  HPB (Oxford)       Date:  2012-08-26       Impact factor: 3.647

3.  Use of a saline-coupled bipolar sealer open liver resection for hepatic malignancy: Medical resource use and costs.

Authors:  Christine I Nichols; Joshua G Vose
Journal:  World J Gastroenterol       Date:  2016-12-14       Impact factor: 5.742

4.  Efficacy of a half-grip technique using a fine tip LigaSure™, Dolphin Tip Sealer/Divider, on liver dissection in swine model.

Authors:  Yoichi Toyama; Seiya Yoshida; Ryota Saito; Ryota Iwase; Koichiro Haruki; Norimitsu Okui; Jun-ichi Shimada; Hiroaki Kitamura; Michinori Matsumoto; Katsuhiko Yanaga
Journal:  BMC Res Notes       Date:  2015-08-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.